Agios Pharmaceuticals (NASDAQ: AGIO)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-28 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.810 | -1.740 | 0.0700 | ||||
REV | 2.710M | 832.000K | -1.878M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Agios Pharmaceuticals (NASDAQ: AGIO) through any online brokerage.
Other companies in Agios Pharmaceuticals’s space includes: Valneva (NASDAQ:VALN), Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Arcutis Biotherapeutics (NASDAQ:ARQT) and FibroGen (NASDAQ:FGEN).
The latest price target for Agios Pharmaceuticals (NASDAQ: AGIO) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 16.00 expecting AGIO to fall to within 12 months (a possible -31.51% downside). 14 analyst firms have reported ratings in the last year.
The stock price for Agios Pharmaceuticals (NASDAQ: AGIO) is $23.36 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Agios Pharmaceuticals.
Agios Pharmaceuticals’s Q2 earnings are confirmed for Thursday, July 28, 2022.
There is no upcoming split for Agios Pharmaceuticals.
Agios Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.